Evidence map›Paper›PMID 18828974›Full record

ReviewMayo Clinic proceedings2008

Treatment of myeloma: cure vs control.

S Vincent Rajkumar

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Mayo Clinic proceedings, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

S Vincent RajkumarDivision of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. rajkumar.vincent@mayo.edu

Funding

TISSUE BANK AND CLINICAL/LABORATORY DATABASEP01CA062242 · NCI · MAYO CLINIC ROCHESTER · PI THERNEAU, TERRY M · 1994 to 2009
$12.9M
Treatment of Early Stage Multiple MyelomaR01CA100080 · NCI · MAYO CLINIC ROCHESTER · PI RAJKUMAR, S VINCENT · 2003 to 2006
$1.1M
Angiogenesis and thalidomide therapy in multiple myelomaR01CA093842 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI RAJKUMAR, S VINCENT · 2002 to 2004
$846k
ANGIOGENESIS AND ANGIOGENIC CYTOKINES IN MYELOMAR21CA085818 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI RAJKUMAR, S VINCENT · 2000 to 2001
$282k
NCI NIH HHS CA100080NCI NIH HHS CA62242NCI NIH HHS CA85818NCI NIH HHS CA93842NCI NIH HHS P01 CA062242NCI NIH HHS R01 CA093842NCI NIH HHS R01 CA100080NCI NIH HHS R21 CA085818
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsHumansMultiple MyelomaStem Cell TransplantationSurvival RateTreatment OutcomeUnited StatesAntineoplastic Agents

Identifiers

PMID18828974
PMCPMC3923461

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.